Cargando…

The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor-κB and Bruton’s Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell Interactions

Circulating platelets establish a variety of immunological programs and orchestrate inflammatory responses at the endothelium. Platelets express the innate immunity family of Toll-like receptors (TLRs). While TLR2/TLR1 ligands are known to activate platelets, the effects of TLR2/TLR6 ligands on plat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parra-Izquierdo, Iván, Lakshmanan, Hari Hara Sudhan, Melrose, Alexander R., Pang, Jiaqing, Zheng, Tony J., Jordan, Kelley R., Reitsma, Stéphanie E., McCarty, Owen J. T., Aslan, Joseph E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435771/ https://www.ncbi.nlm.nih.gov/pubmed/34527000 http://dx.doi.org/10.3389/fimmu.2021.729951

Ejemplares similares

Effect of antiplatelet agents and tyrosine kinase inhibitors on oxLDL-mediated procoagulant platelet activity
por: Zheng, Tony J., et al.
Publicado: (2022)

Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam(1)CSK(4) and Pam(3)CSK(4)
por: Megy, Simon, et al.
Publicado: (2020)

Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton’s Tyrosine Kinase
por: Duan, Rundan, et al.
Publicado: (2021)

Regulation of the mTOR-Rac1 axis in platelet function
por: Aslan, Joseph E., et al.
Publicado: (2012)

An efficient and scalable synthesis of potent TLR2 agonistic PAM(2)CSK(4)
por: Kaur, Arshpreet, et al.
Publicado: (2018)

Platelet reactivity and platelet count in women with iron deficiency treated with intravenous iron
por: Elstrott, Benjamin K., et al.
Publicado: (2022)

Data detailing the platelet acetyl-lysine proteome
por: Aslan, Joseph E., et al.
Publicado: (2015)

Apoptosis regulation by the tyrosine-protein kinase CSK
por: Fortner, Andra, et al.
Publicado: (2022)

Coinjection with TLR2 Agonist Pam3CSK4 Reduces the Pathology of Leishmanization in Mice
por: Huang, Lu, et al.
Publicado: (2015)

Characterization of the Rac guanine nucleotide exchange factor P-Rex1 in platelets
por: Aslan, Joseph E, et al.
Publicado: (2011)

Differential Effects of the Toll-Like Receptor 2 Agonists, PGN and Pam3CSK4 on Anti-IgE Induced Human Mast Cell Activation
por: Yu, Yangyang, et al.
Publicado: (2014)

A20 Is Critical for the Induction of Pam3CSK4-Tolerance in Monocytic THP-1 Cells
por: Hu, Jinyue, et al.
Publicado: (2014)

Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
por: Naylor-Adamson, Leigh, et al.
Publicado: (2021)

Control of Methicillin-Resistant Staphylococcus aureus Pneumonia Utilizing TLR2 Agonist Pam3CSK4
por: Chen, Yi-Guo, et al.
Publicado: (2016)

Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib
por: Claude, Livia, et al.
Publicado: (2022)

The Synthetic Bacterial Lipopeptide Pam3CSK4 Modulates Respiratory Syncytial Virus Infection Independent of TLR Activation
por: Nguyen, D. Tien, et al.
Publicado: (2010)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
por: Kuter, David, et al.
Publicado: (2023)

The Tyrosine Kinase Csk Dimerizes through Its SH3 Domain
por: Levinson, Nicholas M., et al.
Publicado: (2009)

Regulation of Src and Csk Nonreceptor Tyrosine Kinases in the Filasterean Ministeria vibrans
por: Schultheiss, Kira P., et al.
Publicado: (2014)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Control of lymphopoiesis by p50csk, a regulatory protein tyrosine kinase
Publicado: (1995)

Dissection of the catalytic and regulatory structure-function relationships of Csk protein tyrosine kinase
por: Sun, Gongqin, et al.
Publicado: (2023)

Adjuvant Pam3CSk4 does not improve the immunization against Cryptococcus gattii infection in C57BL/6 mice
por: de Campos, Gabriela Yamazaki, et al.
Publicado: (2023)

Toll-like Receptor 1/2 Agonist Pam3CSK4 Suppresses Lipopolysaccharide-driven IgG1 Production while Enhancing IgG2a Production by B Cells
por: Lee, Sang-Hoon, et al.
Publicado: (2018)

Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses
por: Qiao, Yidan, et al.
Publicado: (2022)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
por: Martin, Elodie, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lgrvqd2oogqfhpviplg6jabm9j